ALBANY, N.Y., June 23, 2021 /PRNewswire/--Gemcitabine hydrochloride (HCL), an antimetabolite nucleoside analogue, has been increasingly used a novel oncology product for various cancer types. It has been approved notably for treatment of breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic cancer, and bladder cancer. Gemcitabine HCL has been studied for its cytotoxic effect in various types of tumours treatment, including oesophageal cancer. A sizable chunk of revenues have come from the commercialization of the oncology product Gemzar by Eli Lilly and Company. The company has reaped in profit by the marketing of its products for various cancer types for which gemcitabine HCL had been approved.
Pharmaceutical heavyweights dotting the competitive landscape are expected to accelerate research of combination therapies where gemcitabine HCL is used in drug delivery systems. A clutch of gemcitabine API manufacturers are exploring low-cost manufacturing units in the developing world countries.
Intense research on cancer research on improving the survival rate of numerous cancers has propelled drug makers to grow their stakes in the market. Globally, the market is expected to clock CAGR of around 7% from 2019 to 2027.
Pancreatic Cancer Emerges as a Huge Untapped Segment: Pancreatic cancer, one of the cancers with high mortality, has a typical survival rate of 6–8%. The cancer has been proved to be one of the deadliest in the U.S. in recent years. Elsewhere, the morbidity is high, usually in elderly patients. Currently, there exists a large unmet need for drugs and drug delivery vehicles that can offer superior therapeutic benefits. Gemcitabine as combination therapy is gathering considerable attention among researchers. A growing body of studies on its pharmacology has spurred the revenue potential of players in this segment. The segment held the major share in 2018, and is expected to offer abundant growth avenues in near future as well.
Need for Cost-Effective Generic Cancer Drugs Lends Massive Growth Impetus: Over the past few years, the need for cost-effective drugs for cancer treatment has gained considerable attention among health systems as well as from patients. The patent expiry of several blockbuster drugs in the oncology segment has further whet the appetite of companies working in on anticancer drugs.
Multi-Channel Engagement Based on Digital Channels Gathers Momentum: Medical researchers have gained massively from the use of digital channels. Industry players have leveraged these channels for a multi-channel engagement with their stakeholders across the market's value chain. They are also entering into new strategic partnerships to advance their hold on digital channels for navigating the regulatory complexity.
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision."